GSK’s Breo Fails To Reach Peak In SUMMIT Survival Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The UK pharma had pinned much of its long-term hopes for Breo on successful results of SUMMIT, which compared the morbidity and mortality of COPD patients at increased risk of cardiovascular disease taking Breo versus placebo.
You may also be interested in...
Kalydeco Expands Indication Without Clinical Data; Keytruda Is Latest Bladder Cancer Approval
Keeping track of US FDA approvals last week included watching the creative and the familiar.
Real World Superiority Data May Not Be Enough To Boost GSK's Breo In COPD
Breo Ellipta is associated with a lower rate of exacerbations in real world Salford study, but some analysts question whether it's too late to turn performance around in a highly competitive, highly price-conscious market.
GSK Lays Out Five-Year Growth Strategy, Underpinned By Advair Generics
The company’s five-year forecast includes the entry of Advair generics for the first time, but CEO Andrew Witty says pharma sales will nonetheless grow at low single-digits from 2016 to 2020.